U.S. says Abbott units to pay $160 million to resolve alleged false Medicare claims By Reuters

© Reuters. FILE PHOTO: Boxes of Abbott’s heart stents are pictured inside a store at a hospital in New Delhi, India, April 27, 2018.

(Reuters) – Two units of Abbott Laboratories (NYSE:) will pay $160 million to resolve claims they violated the federal False Claims Act by submitting false claims to Medicare, the U.S. Department of Justice said on Monday.

The Justice Department settled with Arriva Medical LLC, once the largest Medicare mail-order diabetic testing supplier, and its parent Alere Inc. Abbott bought both companies in 2017 after the alleged wrongful conduct took place, the department said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button